The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants

Asthma Clinical Trial

— PEBBLES  

Official title:

THE PEBBLES STUDY: A Randomised Controlled Trial to Prevent Eczema, Food Allergy and Sensitisation Using a Skin Barrier Improvement Strategy

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03667651
• Other study ID #: HREC/17/RCHM/221
• Secondary ID: ACTRN12617001380
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 6, 2018
• Est. completion date: May 31, 2027

Study information

• Verified date: May 2023
• Source: University of Melbourne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants.

A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.

Description:

The primary objective of this study is to demonstrate that twice daily application of a ceramide dominant emollient reduces the risk of eczema and food allergy, when compared to standard skin management. Secondary objectives are to determine if twice daily application of a ceramide dominant emollient reduces the risk of infants developing allergic sensitisation (as measured by skin prick test); to determine if twice daily application of a ceramide dominant emollient improves infant skin barrier function; to determine the level of parental compliance with a program to build infant skin barrier function; to confirm that a ceramide dominant emollient does not cause adverse effects in infants; to determine the level of compliance required to demonstrate an improvement in infant skin barrier function and to determine if twice daily application of a ceramide dominant emollient influences infant skin microbial colonisation, or skin lipid profile.

This is a phase III, single blind (outcome assessor is blinded), randomised controlled multicentre trial of the effect of EpiCeram emollient for improving and maintaining skin barrier function and reducing incidence of eczema and food allergy in high risk infants.

A total of 760 participants with a first degree family history of allergic disease (asthma, eczema, allergic rhinitis or food allergy) will be recruited (380 each group) from maternity wards of three hospitals.

Treatment will be from birth until six months, with a six week, six month and twelve month follow-up. An initial assessment will be performed at baseline which incorporates three surveys, a skin assessment, diary card (which is to be completed weekly and measures compliance), a breast milk sample, guthrie card and tape stripping. The six week and six month assessments entail a skin assessment, survey, compliance check, breast milk sample, tape stripping and guthrie card. Primary outcomes are assessed at the 12 month follow up where in addition to the aforementioned items, a saliva sample will also be taken and skin prick testing and food challenges will be performed when children have a positive SPT to one or more foods..

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 760
• Est. completion date: May 31, 2027
• Est. primary completion date: May 31, 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 3 Weeks

Eligibility

Inclusion Criteria:

Infants will be eligible for this study if their mother, father, or an older sibling has a self-reported history of at least one of the following conditions:

• asthma,

• eczema/atopic dermatitis,

• hay fever/ allergic rhinitis or

• food allergy

Exclusion Criteria: infants with any of the following will be excluded:

• A parent who has a known hypersensitivity to any of the ingredients of EpiCeram™ will be excluded, as it would be difficult for these parents to apply EpiCeram™ to their infant, and there is likely to be an increased risk of the infant reacting to the cream.

• Multiple births (twins, triplets etc.) will be excluded, due to the difficulty in randomising individual twins and because of the clustering effect of multiple children from the same family which would reduce the effective sample size of the study.

• Who are born premature (<36 weeks) as the effect of the intervention may be different in premature infants.

• Who have major birth or early life medical complications that require admission into a special care nursery, as it will be difficult for parents to comply with the study requirements.

• Whose parents do not have sufficient English language skills to be able to answer questions.

• Whose parents are not able to comply with all protocol required visits and procedures

Related Conditions & MeSH terms

• Allergy;Food
• Asthma
• Eczema
• Food Hypersensitivity
• Hypersensitivity

Intervention

Drug:
• EpiCeram
Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.

Locations

Country	Name	City	State
Australia	Mercy Women's Hospital	Heidelberg	Victoria
Australia	Frances Perry Private Hospital	Parkville	Victoria
Australia	Murdoch Children's Research Institute	Parkville	Victoria
Australia	Royal Women's Hospital	Parkville	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
University of Melbourne

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of eczema	as assessed using i) the UK working party criteria for eczema and/or ii) blinded investigator observed eczema.	12 months of age.
Primary	Confirmed diagnosis of food allergy at 12 months (52 weeks).	This diagnosis is derived from a combination of allergic sensitisation, reaction history and food challenge. A skin prick test to six common allergens will be performed (egg white, cows' milk, peanut, dust mite, cat dander, and rye grass) along with a negative (saline) and a positive (histamine) control. Participants that are sensitised to certain foods (>=1mm wheal) during the skin prick testing will be given a challenge to determine if they are allergic to those foods. This will be conducted at the MCRI Allergy Clinic under the supervision of a Doctor specifically trained in oral food challenges.	12 months of age
Secondary	Eczema severity	assessed using the EASI score	12 months of age
Secondary	Parent report of a community doctor diagnosis of eczema		12 months of age
Secondary	infant skin barrier function	As assessed by Trans-epidermal water loss (Vapometer)	At 6 weeks and 12 months of age
Secondary	Parental compliance with a program to build infant skin barrier function	as assessed by parental completion of weekly diary cards and weighing of the tubes of study cream at each visit	At 6 weeks and 6 months of age.
Secondary	Adverse events	as assessed by the documentation of any untoward medical occurrence in a participant enrolled into this study	From recruitment of infant until final study visit at 12 months of age.
Secondary	skin microbial colonisation, or skin lipid profile	Assessed using skin swabs at baseline, 6 weeks and 12 months of age	At 6 weeks and 6 and 12 months of age